Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
Article
[키워드] adverse event
adverse events
anti-SARS-CoV-2
approach
AS03
cellular immunity
CEPI
clinical study
conducted
COVID-19
COVID-19 pandemic
deviation
displaying
distribution
dose
eligible
Emergency use
enrolled
evaluate
evaluated
flu vaccine
foundation
geometric mean concentration
group
groups
healthy
hospital
Humoral immunity
IgG antibody
immunogenic
immunogenicity
injection site pain
Intervention
intramuscularly
Investment
Local
Melinda Gate
mitigate
myalgia
naïve
nanoparticle
nanoparticle vaccine
neutralizing antibody
observer-blinded
outcome
participant
per-protocol
phase
Placebo
placebo-controlled
primary immunogenicity
Protein
protocol
pseudovirus
randomised
RBD
RBD IgG
reached
reactogenicity
receive
recipient
Recombinant protein
recombinant protein vaccine
Registered
reported
Safety
SARS-CoV-2
SARS-COV-2 infection
second dose
Stage
study enrollment
Support
supported
systemic AE
systemic AEs
T-cell immune responses
the receptor-binding domain
the vaccine
titre
Trial
vaccination
vaccination schedule
Vaccine
wild-type virus
World Health Organization
[DOI] 10.1016/j.eclinm.2022.101569 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.eclinm.2022.101569 PMC 바로가기 [Article Type] Article